Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zasocitinib (TAK-279) in Active Psoriatic Arthritis
NCT05153148Phase 2Completed
- Sponsor
- Takeda
- Start
- Jan 2022
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of zasocitinib in psoriatic arthritis (PsA), sponsored by Takeda. Started Jan 2022; status: completed.
02
Drugs
zasocitinib
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT05153148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05153148.